Biogen (BIIB) PT Raised to $156 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.86 +0.01%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 20 | New: 20
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 20 | New: 20
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn raised the price target on Biogen (NASDAQ: BIIB) to $156.00 (from $149.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
- JD Health International Inc (6618:HK) PT Lowered to HK$60 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
